Summary
Guardant Health, Inc. (GH) reported its first quarter 2019 financial results, showcasing robust revenue growth driven by increased adoption of its precision oncology tests. Total revenue surged by 120% year-over-year to $36.7 million, with precision oncology testing revenue up 103% and development services revenue up 213%. This strong top-line performance reflects significant growth in test volumes, particularly from clinical customers, and expansion in biopharmaceutical collaborations. Despite the substantial revenue increase, the company continued to incur net losses, reporting a net loss of $21.4 million for the quarter, consistent with its strategy of investing heavily in research and development, sales, and marketing to fuel future growth. The company ended the quarter with a strong liquidity position, holding $153.8 million in cash and cash equivalents and $339.0 million in marketable securities, indicating sufficient funding for its operational plan for at least the next 12 months. Key strategic developments include progress in securing payer coverage, with a notable proposed Local Coverage Determination (LCD) from Palmetto GBA that could significantly expand Medicare coverage for its Guardant360 test. The company also highlighted ongoing development in its LUNAR early detection program and the recent acquisition of Bellwether Bio, Inc., signaling continued investment in innovation and expansion into new market segments like early cancer detection and screening. Management remains focused on expanding its commercial footprint, both domestically and internationally, and advancing its pipeline of diagnostic solutions.
Financial Highlights
47 data points| Revenue | $36.66M |
| R&D Expenses | $16.32M |
| Operating Expenses | $60.32M |
| Operating Income | -$23.66M |
| Interest Expense | $293K |
| Net Income | -$26.05M |
| EPS (Basic) | $-0.30 |
| Shares Outstanding (Basic) | 85.94M |
Key Highlights
- 1Total revenue for Q1 2019 increased by 120% to $36.7 million, driven by a 103% increase in precision oncology testing revenue and a 213% increase in development services revenue.
- 2The company reported a net loss of $21.4 million for the quarter, consistent with ongoing investments in R&D and commercial expansion.
- 3Cash, cash equivalents, and marketable securities totaled $492.8 million as of March 31, 2019, providing a strong liquidity position.
- 4Significant progress was made in securing payer coverage, with a proposed Medicare Local Coverage Determination (LCD) that could expand access to the Guardant360 test.
- 5Test volumes for clinical customers increased to 9,521 in Q1 2019 from 7,246 in Q1 2018.
- 6The company completed the acquisition of Bellwether Bio, Inc. in April 2019, aimed at advancing early blood-based cancer detection capabilities.
- 7Research and development expenses increased significantly by 98% to $16.3 million, reflecting continued investment in product innovation, including the LUNAR program.